Arzimanoglou Alexis, Brandl Ulrich, Cross J Helen, Gil-Nagel Antonio, Lagae Lieven, Landmark Cecilie Johannessen, Specchio Nicola, Nabbout Rima, Thiele Elizabeth A, Gubbay Oliver
Paediatric Epilepsy Dpt., University Hospitals of Lyon (HCL), Member of the ERN EpiCARE, and Inserm U1028/CNRS UMR5292, Lyon, France
Department of Neuropediatrics, University Hospital Jena, Jena, Germany
Epileptic Disord. 2020 Feb 1;22(1):1-14. doi: 10.1684/epd.2020.1141.
The growing interest in cannabidiol (CBD), specifically a pure form of CBD, as a treatment for epilepsy, among other conditions, is reflected in recent changes in legislation in some countries. Although there has been much speculation about the therapeutic value of cannabis-based products as an anti-seizure treatment for some time, it is only within the last two years that Class I evidence has been available for a pure form of CBD, based on placebo-controlled RCTs for patients with Lennox-Gastaut syndrome and Dravet syndrome. However, just as we are beginning to understand the significance of CBD as a treatment for epilepsy, in recent years, a broad spectrum of products advertised to contain CBD has emerged on the market. The effects of these products are fundamentally dependent on the purity, preparation, and concentration of CBD and other components, and consensus and standardisation are severely lacking regarding their preparation, composition, usage and effectiveness. This review aims to provide information to neurologists and epileptologists on the therapeutic value of CBD products, principally a purified form, in routine practice for patients with intractable epilepsy.
大麻二酚（CBD），特别是纯形式的CBD，作为治疗癫痫及其他病症的方法，受到越来越多的关注，这在一些国家近期的立法变化中得到了体现。尽管一段时间以来，人们对基于大麻的产品作为抗癫痫治疗方法的治疗价值有诸多猜测，但直到最近两年，才有基于针对伦诺克斯 - 加斯东综合征和德雷维特综合征患者的安慰剂对照随机对照试验（RCT）的一级证据，证明了纯形式的CBD的有效性。然而，就在我们开始理解CBD作为癫痫治疗方法的重要性时，近年来，市场上出现了大量宣称含有CBD的产品。这些产品的效果从根本上取决于CBD和其他成分的纯度、制剂和浓度，而且在其制备、成分、用法和有效性方面严重缺乏共识和标准化。本综述旨在向神经科医生和癫痫专家提供有关CBD产品，主要是纯化形式的CBD产品，在难治性癫痫患者常规治疗中的治疗价值的信息。
